Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422175
Status:
COMPLETED
Last Update Posted:
2007-11-29
First Post:
2007-01-11
Brief Title:
Single Dose Study to Assess the Safety Tolerability Concentration in Body and Effect of BAF312
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A First-in-Human Study for BAF312 A Two Parts Single Center Randomized Double-Blind Placebo-Controlled Ascending Single Dose Study to Explore the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability and effect of oral BAF312 on bodily functions as well as the bodys absorption distribution metabolism and excretion of BAF312 in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None